2023
Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
Gottlieb J, Fischer B, Schupp J, Golpon H. Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors. PLOS ONE 2023, 18: e0284653. PMID: 37200246, PMCID: PMC10194991, DOI: 10.1371/journal.pone.0284653.Peer-Reviewed Original ResearchConceptsCNI-free immunosuppressionCalcineurin inhibitor-free immunosuppressionMTOR inhibitorsFree immunosuppressionLung transplantationImproved survivalRapamycin inhibitorsNeurological diseasesSingle-center case-control studyCenter case-control studyCNI-free regimenCurative treatment optionGlomerular filtration rateMajority of patientsNon-malignant indicationsSignificant functional improvementCase-control studyMechanistic targetAcute rejectionLTx patientsNeurological complicationsAdult patientsMedian durationSingle centerTreatment options
2022
Feasibility of Prolonged Calcineurin-Inhibitor Free Immunosuppression After Lung Transplantation - A Retrospective Single Center Analysis
Gottlieb J, Valtin C, Fischer B, Schupp J, Golpon H. Feasibility of Prolonged Calcineurin-Inhibitor Free Immunosuppression After Lung Transplantation - A Retrospective Single Center Analysis. The Journal Of Heart And Lung Transplantation 2022, 41: s421. DOI: 10.1016/j.healun.2022.01.1061.Peer-Reviewed Original ResearchProliferation signal inhibitorsCalcineurin inhibitor-free immunosuppressionChronic lung allograft dysfunctionRetrospective single-center analysisSingle-center analysisFree immunosuppressionCurative intentionMedian glomerular filtration rateCenter analysisCNI-free immunosuppressionLung allograft dysfunctionTriple-drug regimenGlomerular filtration rateNon-malignant indicationsAllograft dysfunctionEvaluable patientsIS regimenLung transplantationTriple regimenNeurological complicationsPalliative settingDrug regimenInduction agentCase reportFiltration rate